Eli M. Wallace - 10 Dec 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Role
Chief Executive Officer, Director
Signature
/s/ Aaron Chan, Attorney-in-Fact
Issuer symbol
HLXB
Transactions as of
10 Dec 2025
Net transactions value
$0
Form type
4
Filing time
12 Dec 2025, 19:04:11 UTC
Previous filing
06 Oct 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wallace Eli M. Chief Executive Officer, Director BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO /s/ Aaron Chan, Attorney-in-Fact 12 Dec 2025 0001776352

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBOT Stock Option (Right to Buy) Disposed to Issuer -1,114,400 -69% 500,000 10 Dec 2025 Common Stock 1,114,400 $12.44 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2 On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the "Rescinded Portion"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3.